SAN DIEGO, April 15 /PRNewswire/ -- Mr. Glynn has over 34 years of combined financial, operating and director level experience, and is well known within the life sciences industry for his role in the growth and development of several biotechnology companies. Most notably, Mr. Glynn retired from Invitrogen Corporation (Nasdaq: IVGN) in 2003 where, during his tenure with the company, he held several operating roles including CFO, President and COO and CEO. During this time, Mr. Glynn led the company through several stages of growth including an IPO, numerous financings and several acquisitions including Novex, GIBCO Life Technologies, Research Genetics and Molecular Probes. Mr. Glynn, following his retirement from Invitrogen Corporation, remained on the company's board of directors until April 2006.
"We are very pleased to be adding someone of Jim's reputation and
experience to our board," said Todd R. Nelson Ph.D., eBioscience's Chief
Executive Officer. "As an emerging global leader in the cellular analysis
market, we are focused on growing our business operations through the
development and commercialization of a diverse array of products, and also
through the operational execution of several key strategic initiatives. In
his role as director, Mr. Glynn will provide invaluable operating insight,
financial advice and strategic guidance to ensure eBioscience remains a
leader in the life sciences market place." Brian Seed Ph.D., Chairman of
the board of directors for eBioscience added, "We look forward to tapping
Jim's wealth of operating wisdom and the insights gleaned from his decades
of senior management experience in the life science and related industries.
Jim enjoys an enviable reputation among investors and professional fund
|SOURCE eBioscience Corporation|
Copyright©2008 PR Newswire.
All rights reserved